Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of apremilast丨cas 608141-41-9 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications of ApreMilast丨CAS 608141-41-9
|
Appearance |
White to light yellow solid crystal |
|
Purity |
99.0% min |
|
Assay |
98% - 102% |
|
Identification |
IR absorption spectrum and retention time consistent with reference |
|
1,3-Dioxo-2-isoindolineacetic acid |
0.1% max |
|
(S)-13-O-hydroxy-4-Methyl-methyloyl)ethylamide N-acetyl-L-leucine salt |
0.1% max |
|
Unknown single impurity |
0.1% max |
|
Total impurities |
1.0% max |
|
Melting point |
154 - 158 °C |
|
Heavy metals |
10 ppm max |
|
Residue on ignition |
0.1% max |
|
Acetone |
5000 ppm max |
|
Ethanol |
5000 ppm max |
|
Dichloromethane |
600 ppm max |
|
Water |
0.5% max |
|
Loss on drying |
0.5% max |
|
Chiral isomers |
1.0% max |
Transport Information of ApreMilast丨CAS 608141-41-9
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2933990099306 |
|
Stability & Reactivity |
The following applies in general to flammable organic |
|
Storage |
Tightly closed. Dry. Combustible Solids Recommended storage temperature : -25 - -10 °C |
|
Condition to Avoid |
|
|
Package |
Manufacturing Information of ApreMilast丨CAS 608141-41-9
|
Parameter |
Specification |
|
Capacity |
|
|
Frequency |
|
|
Main Export Countries |
|
|
Capacity/Batch |
|
|
Experience |
Production since 2005 |
|
Stock |
Small quantity in stock |
ApreMilast丨CAS 608141-41-9 is an orally administered small-molecule drug known for its anti-inflammatory and immunomodulatory properties. It functions as a selective phosphodiesterase 4 (PDE4) inhibitor and is mainly used in the treatment of autoimmune and inflammatory diseases.
Primary Applications of ApreMilast丨CAS 608141-41-9
1. Psoriasis and Psoriatic Arthritis
● Approved treatment for moderate to severe plaque psoriasis.
● Reduces skin inflammation, scaling, and joint pain.
● Alternative to biologic agents; convenient oral administration.
2. Behçet's Disease
● FDA-approved for treatment of oral ulcers associated with Behçet's disease.
● Offers effective symptom control with a good safety profile.
3. Atopic Dermatitis and Other Autoimmune Disorders (investigational)
● Under investigation or off-label use for:
o Atopic dermatitis
o Rheumatoid arthritis
o Lupus erythematosus
o Inflammatory bowel disease (IBD)
4. Potential Antiviral/Antifibrotic Uses (emerging research)
● PDE4 inhibitors like apremilast are being studied for their immune-modulating roles in viral infections and fibrotic diseases (e.g., pulmonary fibrosis).
Benefits of ApreMilast丨CAS 608141-41-9
✅ Oral Dosage Form
● No injections or infusions needed, enhancing patient convenience and compliance.
✅ Targeted Immunomodulation
● Balances cytokine signaling without broad immune suppression, reducing the risk of infections and cancer.
✅ Well-Tolerated
● Most side effects are mild to moderate (e.g., nausea, diarrhea, headache) and often resolve over time.
✅ Steroid- and Biologic-Sparing Agent
● Allows reduction or avoidance of corticosteroids and injectable biologics.
Conclusion
ApreMilast丨CAS 608141-41-9 is a cutting-edge PDE4 inhibitor offering a non-biologic oral treatment option for chronic inflammatory diseases like psoriasis, psoriatic arthritis, and Behçet's disease. Its balanced efficacy, safety profile, and oral administration position it as a valuable therapeutic agent in autoimmune and inflammatory conditions.
Hot Tags: apremilast丨cas 608141-41-9, China apremilast丨cas 608141-41-9 manufacturers, suppliers, factory, 59-30-3, CAS 107133 36 8, Ciclopirox ethanolamine, CAS 39537 23 0, CAS 98319 26 7, CAS 1263 89 4

